BGPT: Paper Review: Recent Advances in Nanomaterial-Based Aptasensors in Medical Diagnosis and Therapy

Explore by Goal

Quick Answer Copied

Nanomaterial-based aptasensors: a wide (but not deeply quantitative) 2021 review

The paper surveys aptamer selection (SELEX variants) and nanomaterial transducers (AuNPs, QDs, CQDs, MoS₂, CNTs, graphene/GO) for medical diagnosis/therapy, reporting many representative assay metrics (e.g., LODs/linear ranges) but with limited synthesis that would enable rigorous cross-paper effect-size comparisons.

Key critique: it is strong as a taxonomy/landscape overview, weaker as a scientific meta-assessment because it does not normalize assay conditions, units, matrices, or reporting completeness across studies.

Long Answer

Paper Review (Science-grounded, critical): Recent Advances in Nanomaterial-Based Aptasensors in Medical Diagnosis and Therapy

Published: 6 Apr 2021 • DOI: 10.3390/nano11040932 • Type: Narrative review

Visual map of what the paper covers

The figure is a conceptual decomposition based on the paper’s section structure: selection protocol → nanomaterial aptasensors → signal types/diagnostic applications → future perspectives & challenges.

A quantitative “where the numbers are” check (from the paper’s own extracted tables)

The review includes representative aptasensor performance values (linear ranges and LODs) in its summary tables (notably Table 2).

Normalization warning (skeptical but important) Units and reporting completeness differ across entries (some LODs/linear ranges are “-”), and assays come from different papers without harmonized matrices, protocols, calibration curves, or statistics—so cross-bar comparisons are descriptive, not causal or predictive.

1) LODs by sensor example (log10 scale where possible)

I can’t safely plot log10(LOD) with unit mixing or implicit conversions without potentially introducing errors not stated in the paper.

2) A safer visualization: which signal modality dominates (based on Table 2 signal labels)

The counts are directly based on the signal labels present in the review’s Table 2 in the provided full-text excerpt.

3) Nanomaterial class coverage (descriptive taxonomy)

This figure is intentionally a sketch: the provided text shows the major sections on AuNPs, QDs, CQDs/CDs, MoS₂, CNTs, and graphene/GO/rGO, plus shorter sections for other nanomaterials. The review’s exact mention-frequency is not computed here because the provided content is incomplete for a full-text wordcount audit.

Mechanistic themes the review emphasizes (and what’s uncertain)

Theme A — Aptamer selection bottlenecks and SELEX variants

Baseline SELEX: SELEX uses an oligo library (random middle + fixed primer regions), separates bound from unbound, elutes, and amplifies by PCR, iterating ~10–15 cycles (weeks) to enrich high-affinity sequences.
Modified SELEX: The review discusses accelerated or biased-selection approaches (e.g., acoustophoretic SELEX, CE-SELEX, fractional collection, cell-SELEX, Hi-Fi SELEX, click-SELEX, ddPCR-assisted SELEX, etc.) but indicates “mixed success” across modifications.

Theme B — Nanomaterials as transducers (signal modality depends on properties)

The review argues that aptamer recognition plus nanomaterial transduction yields sensitive POC aptasensors, with signals including optical/colorimetric, electrochemical, fluorescence/FRET, SERS, SPR, and ECL.
For AuNPs, it specifically highlights localized surface plasmon resonance (LSPR)-driven color change upon dispersion/aggregation.
For graphene/GO, it emphasizes quenching and FRET/turn-on designs, while noting synthesis/transfer scalability challenges in practice.

Theme C — Therapeutic potential is mentioned, but evidence type varies

The review reports that some aptasensor constructs show therapeutic effects (e.g., aptamer–nanomaterial platforms that deliver agents or inhibit tumor growth), but it also states setbacks such as toxicity to human cells and uneven evidence depth across examples.
Example therapeutic narratives include QD/doxorubicin FRET delivery concepts and carbon nanodot/aptamer tumor inhibition claims in referenced studies, but the review does not provide a uniform translational risk framework (e.g., biodistribution, long-term toxicity, clearance).

Table extraction audit (useful, but incomplete for rigorous comparison)

The included Table 2 examples show clear breadth (toxins, cytokines, cardiac markers, bacteria, small molecules, cancer biomarkers).

Aptasensor (Table 2)	Signal type	Target	Linear range (as reported)	LOD (as reported)
AuNPs–SEB aptamer	Colorimetry	Staphylococcal enterotoxin B	50 µg/mL–0.5 ng/mL	50 ng/mL
AuNPs–IL-6 aptamer	Colorimetry	Interleukin-6	3.3–125 µg/mL	1.95 µg/mL
AuNPs–thio/27-mer aptamer	Colorimetry	Thrombin	5 pM–2 nM	5 pM
AuNPs+[Ru(NH3)6]3+ / TBA1,TBA2	Electrochemical	Thrombin	1 fM–6 pM	0.1429 fM
CDS-QDs/AuNPs/Tro6 aptamer	ECL	Cardiac troponin I	1 fg/mL–10 ng/mL	0.75 fg/mL
CdS-NCs/AuNPs/luminol	Ratiometric ECL	Thrombin	-	500 fg/mL
CDs/AS1411 aptamer	Spectrofluorometry	Cancer cells	-	~100 cells/mL
MoS2-NS aptamer	Fluorescence	PSA	-	0.2 ng/mL
AuNPs/TiONBs/MC-LR aptamer	Electrochemical	Microcystin-LR	0.005–30 nM	0.002 nM
SWCNTs–PBASE aptamer	FET	Cathepsin K	2.3 pM–0.23 nM	-
Graphene/SH-SAW aptamer	Surface Acoustic Wave	Endotoxins	0–100 ng/mL	3.53 ng/mL
GO/33-mer aptamer	Fluorescence	Theophylline	1–100 µM	0.155 µM
rGO-PET/cTnT aptamer	Electrical	Cardiac troponin T	0.001–10 ng/mL	1.2–1.7 pg/mL

The table content is reconstructed from the review’s Table 2 entries visible in the provided full-text excerpt.

Skeptical critique: strengths, gaps, and “what could disprove”

Strengths

Good landscape coverage: It spans aptamer selection workflows and multiple nanomaterial transducers tied to distinct signal modalities.
Useful compilation of representative metrics: Table 2 provides concrete LOD/linear range examples across targets such as IL-6 and thrombin.

Major gaps & potential biases

No normalization / meta-analysis: Because the performance values originate from heterogeneous studies and are not normalized to assay conditions, readers cannot reliably infer general superiority or clinical feasibility.
Incomplete reporting in the summary table: Some entries omit LOD/linear range, preventing consistent visualization or ranking.
Therapeutic claims are not uniformly risk-assessed: The review mentions toxicity setbacks and theranostic potential, but does not unify biodistribution, clearance, long-term safety, or immunogenicity assessment across cited constructs.

Where the paper’s narrative could be wrong (falsifiable targets)

Reproducibility risk: Even if LODs are excellent in buffer, performance can degrade in real matrices due to fouling, non-specific adsorption, and calibration drift; the review doesn’t provide an end-to-end reproducibility benchmark.
Comparative superiority risk: The review implies nanomaterials improve sensitivity/selectivity vs some traditional methods, but it does not provide controlled head-to-head comparisons.

Why aptasensors are scientifically plausible (supporting references beyond the review)

Independent literature broadly supports that aptamers can be used as recognition elements for bioanalytical applications and that nanomaterial integration can improve analytical performance—yet translating that into consistent real-world performance remains a key scientific/engineering challenge.

Aptamers as bioanalytical recognition elements are discussed in a general analytical chemistry treatment.
Aptamer-based biosensors are reviewed across transduction modalities, noting both strengths (specificity/affinity/design flexibility) and constraints (immobilization/surface issues).

Author-review shortcuts (bespoke BGPT searches)

Feedback:

Updated: April 11, 2026